Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...

A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...

The National Comprehensive Cancer Network (NCCN) published new guidelines for pediatric soft tissue sarcoma (STS), growing the NCCN’s library of guidelines to now cover 91 topics in cancer care. 1 ...

Iovance Biotherapeutics shares rose after the company shared positive trial results from a treatment designed for soft tissue cancer. The stock gained 26% to $3.65 Tuesday. Shares are still down 32% ...

When Jon and Dayla Culp received the news that their six-year-old Labrador retriever, Clarice, had a malignant tumor near her ...

Natco Pharma launched a cheaper generic version of the cancer drug ‘Pomalyst’ in the U.S. to treat multiple myeloma, making ...

Pediatric sarcomas are a significant category within pediatric malignancies, comprising over 20% of solid malignant cancers in children. These cancers are ...

Andreea Anița died on March 3, 11 years after receiving her diagnosis ...

Access the Moleculin CEO Corner here HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next ...

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...